Bambusa Therapeutics Inc.
BBTXHealthcare|Biotechnology|US
$15.73
-0.12 (-0.76%)
Upcoming Data Readouts (6)
Dec 2026
Est. completion
P1Chronic Obstructive Pulmonary Disease (COPD)
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07288554n=68
Jan 2027
Est. completion
P1Chronic Obstructive Pulmonary Disease
A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)
NCT06944925n=286
Feb 2027
Est. completion
P1Atopic Dermatitis
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
NCT06808477n=237
Dec 2027
Est. completion
P1P2Chronic Spontaneous Urticaria
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
NCT07717905n=48
Dec 2027
Est. completion
P1Atopic Dermatitis
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
NCT07239947n=99
Dec 2027
Est. completion
P1P2Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma
NCT07436949n=64